{
    "nct_id": "NCT06637501",
    "official_title": "A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia",
    "inclusion_criteria": "1. Previously untreated adult patient ≥ 18 years with a confirmed diagnosis of CLL.\n2. CLL requiring treatment as per pre-defined criteria.\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2.\n4. Measurable disease by CT/MRI.\n5. Adequate marrow function.\n6. Adequate liver function as indicated by aspartate aminotransferase (AST) alanine aminotransferase (ALT) and serum total bilirubin.\n7. Adequate renal function.\n8. Life expectancy > 6 months.\n9. Signed informed consent and able to comply with the study protocol in the investigator's judgment.\n10. Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 90 days after the last dose of study drug.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation\n2. Known central nervous system involvement\n3. Received previous systemic treatment for CLL\n4. Clinically significant cardiovascular disease\n5. Severe or debilitating pulmonary disease\n6. History of prior malignancy\n7. Active fungal, bacterial, and/or viral infection requiring systemic therapy\n8. Positive HIV serology (HIVAb) status or serologic status reflecting active hepatitis B or C infection\n9. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia requiring treatment\n10. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention\n11. History of stroke or intracranial hemorrhage ≤ 6 months before the first dose of study treatment\n12. Unable to swallow capsules or tablets or diseases significantly affecting GI function\n13. Hypersensitivity to zanubrutinib, sonrotoclax, or any of its excipients\n14. Use of investigational agents within the last 4 weeks before screening\n15. Pregnant and lactating females\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply",
    "miscellaneous_criteria": ""
}